Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 346

Sort by

Sort Order Select

Journal Articles

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

Tomás José González-López, Nuria Bermejo-Vega, Rocío Cardesa-Cabrera, Violeta Martínez-Robles, Gerardo Aguilar-Monserrate, Gloria Pérez-Segura, Abel Domingo, Josefa Luis-Navarro, Sunil Lakhwani, Natalia Acedo, María Luisa Lozano, Silvia Bernat, Ana Torres-Tienza, Ana Ruano, Isidro Jarque, Pilar Galán, Carmen Benet, Shally Marcellini, Reyes Jimenez-Bárcenas, Daniel Martínez-Carballeira, Dunia De Miguel-Llorente, Alvaro Perona-Blázquez, Isabel Gonzalez-Gascón, Elsa Lopez-Ansoar, José María Alonso-Alonso, María Luisa Bengochea-Casado, Francisco Javier Díaz-Gálvez, Ana Moretó, Gemma Moreno-Jiménez, Roberto Hernández-Martin, Erik de Cabo, Julio Dávila-Valls, Amalia Cuesta, Carmen Pastoriza, Gerardo Julio Hermida-Fernández, Covadonga García, Miguel Angel Pozas-Mañas, Carlos Aguilar, Dolores Fernandez-Jimenez, Begoña Navas-Elorza, Carolina López-Santamaría Castro, Alvaro Lorenzo, Xavier Ortín, Marta García, Sonia Piernas, Johana Díaz-Santa, Inmaculada Soto, Drew Provan, Gloria García-Donas Gabaldón

Blood (2024) 144 (6): 646–656.

https://doi.org/10.1182/blood.2024024250

Published: 2024

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, Christopher D’Angelo, Jihyun Ma, Miguel-Angel Perales, Matthew Frigault, Marcela V. Maus

Blood (2024) 143 (20): 2099–2105.

https://doi.org/10.1182/blood.2024024166

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Blood (2023) 142 (Supplement 1): 357.

https://doi.org/10.1182/blood-2023-174728

Published: 2023

Journal Articles

First Time Mexican Report of Next Gene Sequencing (NGS) Panel in Newly Diagnose Acute Myeloid Leukemia (AML). Series of Cases

Nidia Paulina Zapata, Lilian Gomez Abogado, Luis Castellanos Santiago, Alejandro Sosa Espinoza, Miguel Ángel Ramos Arrieta, Diana Arcos, Judith Cruz

Blood (2023) 142 (Supplement 1): 6024.

https://doi.org/10.1182/blood-2023-191076

Published: 2023

Journal Articles

New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?

Belén Sierro-Martínez, Virginia Escamilla Gomez, Laura Perez-Ortega, Beatriz Guijarro-Albaladejo, Paola Hernández-Díaz, María de la Rosa-Garrido, Maribel Lara-Chica, Juan Luis Reguera, Luzalba Sanoja Flores, Blanca Arribas-Arribas, Miguel-Ángel Montiel-Aguilera, Gloria Carmona, Maria-Jose Robles, Teresa Caballero, Javier Briones, Hermann Einsele, Michael Hudecek, Jose A. Pérez-Simón, Estefania Garcia-Guerrero

Blood (2023) 142 (Supplement 1): 6866.

https://doi.org/10.1182/blood-2023-186095

Published: 2023

Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4887.

https://doi.org/10.1182/blood-2023-182837

Published: 2023

Journal Articles

Successful Incorporation of Electronic Patient Reported Outcomes Using Promis-29 into Standard of Care after Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T Cell Therapy

Gunjan L. Shah, Stephanie Lobaugh, Ranjit Sukhu, Sean M. Devlin, Thomas Atkinson, Elizabeth Kemeny, Peter Stetson, Miguel-Angel Perales, Sergio A. Giralt, Michael Scordo

Blood (2023) 142 (Supplement 1): 7382.

https://doi.org/10.1182/blood-2023-179330

Published: 2023

Journal Articles

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Blood (2023) 142 (Supplement 1): 6907.

https://doi.org/10.1182/blood-2023-181999

Published: 2023

Journal Articles

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Giulio Cassanello, Efrat Luttwak, Sean M. Devlin, Alejandro Luna De Abia, Magdalena Corona, Ivan Landego, Allison Parascondola, Amethyst Saldia, Ana Alarcon Tomas, Parastoo B. Dahi, Richard J. Lin, M. Lia Palomba, Jae H. Park, Gilles Salles, Miguel-Angel Perales, Michael Scordo, Roni Shouval, Gunjan L. Shah

Blood (2023) 142 (Supplement 1): 6898.

https://doi.org/10.1182/blood-2023-190500

Published: 2023

Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood (2023) 142 (Supplement 1): 617.

https://doi.org/10.1182/blood-2023-184862

Published: 2023

Journal Articles

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Blood (2023) 142 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2023-189196

Published: 2023

Journal Articles

CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2023-190326

Published: 2023

Journal Articles

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

Eric Davis, Elise Feuer, Candice Rapoport, Stephanie Lobaugh, Sean M. Devlin, Anne Archer, Stephanie Chinapen, Jacob Federman, Amanda Kelly, Elizabeth Klein, Melissa Nhaissi, Deborah Wells, Juliet N Barker, Esperanza B. Papadopoulos, Andromachi Scaradavou, Jaap Jan Boelens, Miguel-Angel Perales, Elena Maryamchik, Roni Tamari

Blood (2023) 142 (Supplement 1): 113.

https://doi.org/10.1182/blood-2023-190940

Published: 2023

Journal Articles

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Blood (2023) 142 (Supplement 1): 7156.

https://doi.org/10.1182/blood-2023-190332

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Blood (2023) 142 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2023-181997

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

NARROW

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

First Time Mexican Report of Next Gene Sequencing (NGS) Panel in Newly Diagnose Acute Myeloid Leukemia (AML). Series of Cases

New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

Successful Incorporation of Electronic Patient Reported Outcomes Using Promis-29 into Standard of Care after Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T Cell Therapy

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only